Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.

Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, Tsai WY, Chen YH, Abrams EJ, Persaud D.

Clin Infect Dis. 2011 Feb 15;52(4):514-21. doi: 10.1093/cid/ciq161. Epub 2011 Jan 22.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams EJ.

AIDS. 2014 Mar;28 Suppl 2:S137-46. doi: 10.1097/QAD.0000000000000240. Review.

PMID:
24849473
5.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
6.

["State of the HAART". Current strategies for antiretroviral therapy].

Staszewski S, Stephan C.

Internist (Berl). 2004 Dec;45(12):1428-36. Review. German.

PMID:
15551021
7.

Defining treatment failure in resource-rich settings.

Aldous JL, Haubrich RH.

Curr Opin HIV AIDS. 2009 Nov;4(6):459-66. doi: 10.1097/COH.0b013e328331dea5. Review.

Supplemental Content

Support Center